Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:GTx,_Inc.
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:CEO |
James Breitmeyer
|
| gptkbp:clinicalTrialPhase |
TK216 for Ewing sarcoma
cirmtuzumab for chronic lymphocytic leukemia |
| gptkbp:developedBy |
experimental cancer therapies
|
| gptkbp:focusesOn |
oncology
cancer therapeutics |
| gptkbp:foundedYear |
2013
|
| gptkbp:hasCompany |
true
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Oncternal Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:leadProductCandidate |
TK216
cirmtuzumab |
| gptkbp:stockSymbol |
ONCT
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://oncternal.com
|
| gptkbp:bfsParent |
gptkb:CARIN_Alliance
gptkb:Sorrento_Mesa |
| gptkbp:bfsLayer |
8
|